Lithium promotes neural precursor cell proliferation: Evidence for the involvement of the non-canonical GSK-3β-NF-AT signaling

Cell and Bioscience

Volumn 1, Issue 1, 2011, Pages

  Qu, Zhaoxia ^a,b   Sun, Dongming ^a   Young, Wise ^a  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052903796     PISSN: None     EISSN: 20453701     Source Type: Journal    
DOI: 10.1186/2045-3701-1-18     Document Type: Article

References (43)

1. Chuang DM. The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann N Y Acad Sci 2005, 1053:195-204. 10.1196/annals.1344.018, 16179524.
2. Wada A, Yokoo H, Yanagita T, Kobayashi H. Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. J Pharmacol Sci 2005, 99:307-321. 10.1254/jphs.CRJ05009X, 16340157.
3. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989, 59:411-419. 10.1016/0092-8674(89)90026-3, 2553271.
4. Lubrich B, van Calker D. Inhibition of the high affinity myo-inositol transport system: a common mechanism of action of antibipolar drugs?. Neuropsychopharmacology 1999, 21:519-529. 10.1016/S0893-133X(99)00037-8, 10481836.
5. Bersudsky Y, Shaldubina A, Agam G, Berry GT, Belmaker RH. Homozygote inositol transporter knockout mice show a lithium-like phenotype. Bipolar Disord 2008, 10:453-459. 10.1111/j.1399-5618.2007.00546.x, 18452441.
6. Shaldubina A, Johanson RA, O'Brien WT, Buccafusca R, Agam G, Belmaker RH, Klein PS, Bersudsky Y, Berry GT. SMIT1 haploinsufficiency causes brain inositol deficiency without affecting lithium-sensitive behavior. Mol Genet Metab 2006, 88:384-388. 10.1016/j.ymgme.2006.03.007, 16644257.
7. Gould TD, Manji HK. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 2005, 30:1223-1237.
8. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996, 6:1664-1668. 10.1016/S0960-9822(02)70790-2, 8994831.
9. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996, 93:8455-8459. 10.1073/pnas.93.16.8455, 38692, 8710892.
10. O'Brien WT, Harper AD, Jove F, Woodgett JR, Maretto S, Piccolo S, Klein PS. Glycogen synthase kinase-3β haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 2004, 24:6791-6798. 10.1523/JNEUROSCI.4753-03.2004, 15282284.
11. Prickaerts J, Moechars D, Cryns K, Lenaerts I, van Craenendonck H, Goris I, Daneels G, Bouwknecht JA, Steckler T. Transgenic mice overexpressing glycogen synthase kinase 3β: a putative model of hyperactivity and mania. J Neurosci 2006, 26:9022-9029. 10.1523/JNEUROSCI.5216-05.2006, 16943560.
12. Eom TY, Jope RS. Blocked inhibitory serine-phosphorylation of glycogen synthase kinase-3α/β impairs in vivo neural precursor cell proliferation. Biol Psychiatry 2009, 66:494-502. 10.1016/j.biopsych.2009.04.015, 2746934, 19520363.
13. Misiuta IE, Saporta S, Sanberg PR, Zigova T, Willing AE. Influence of retinoic acid and lithium on proliferation and dopaminergic potential of human NT2 cells. J Neurosci Res 2006, 83:668-679. 10.1002/jnr.20718, 16408307.
14. Boku S, Nakagawa S, Masuda T, Nishikawa H, Kato A, Kitaichi Y, Inoue T, Koyama T. Glucocorticoids and lithium reciprocally regulate the proliferation of adult dentate gyrus-derived neural precursor cells through GSK-3β and β-catenin/TCF pathway. Neuropsychopharmacology 2009, 34:805-815. 10.1038/npp.2008.198, 19005466.
15. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003, 116:1175-1186. 10.1242/jcs.00384, 3006448, 12615961.
16. Ohteki T, Parsons M, Zakarian A, Jones RG, Nguyen LT, Woodgett JR, Ohashi PS. Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3. J Exp Med 2000, 192:99-104. 10.1084/jem.192.1.99, 1887707, 10880530.
17. Graef IA, Mermelstein PG, Stankunas K, Neilson JR, Deisseroth K, Tsien RW, Crabtree GR. L-type calcium channels and GSK-3 regulate the activity of NF-ATc4 in hippocampal neurons. Nature 1999, 401:703-708. 10.1038/44378, 10537109.
18. Beals CR, Sheridan CM, Turck CW, Gardner P, Crabtree GR. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 1997, 275:1930-1934. 10.1126/science.275.5308.1930, 9072970.
19. Hasegawa K, Chang YW, Li H, Berlin Y, Ikeda O, Kane-Goldsmith N, Grumet M. Embryonic radial glia bridge spinal cord lesions and promote functional recovery following spinal cord injury. Exp Neurol 2005, 193:394-410. 10.1016/j.expneurol.2004.12.024, 15869942.
20. Choi WS, Sung CK. Effects of lithium and insulin on glycogen synthesis in L6 myocytes: additive effects on inactivation of glycogen synthase kinase-3. Biochim Biophys Acta 2000, 1475:225-230.
21. Hongisto V, Smeds N, Brecht S, Herdegen T, Courtney MJ, Coffey ET. Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3. Mol Cell Biol 2003, 23:6027-6036. 10.1128/MCB.23.17.6027-6036.2003, 180950, 12917327.
22. Beurel E, Kornprobst M, Blivet-Van Eggelpoel MJ, Ruiz-Ruiz C, Cadoret A, Capeau J, Desbois-Mouthon C. GSK-3β inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression. Exp Cell Res 2004, 300:354-364. 10.1016/j.yexcr.2004.08.001, 15475000.
23. Jonathan Ryves W, Dalton EC, Harwood AJ, Williams RS. GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid. Bipolar Disord 2005, 7:260-265. 10.1111/j.1399-5618.2005.00194.x, 1249491, 15898963.
24. Li X, Friedman AB, Zhu W, Wang L, Boswell S, May RS, Davis LL, Jope RS. Lithium regulates glycogen synthase kinase-3β in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder. Biol Psychiatry 2007, 61:216-222. 10.1016/j.biopsych.2006.02.027, 1853347, 16806104.
25. Frey BN, Andreazza AC, Rosa AR, Martins MR, Valvassori SS, Reus GZ, Hatch JP, Quevedo J, Kapczinski F. Lithium increases nerve growth factor levels in the rat hippocampus in an animal model of mania. Behav Pharmacol 2006, 17:311-318. 10.1097/01.fbp.0000205013.59455.09, 16914949.
26. Walz JC, Frey BN, Andreazza AC, Cereser KM, Cacilhas AA, Valvassori SS, Quevedo J, Kapczinski F. Effects of lithium and valproate on serum and hippocampal neurotrophin-3 levels in an animal model of mania. J Psychiatr Res 2008, 42:416-421. 10.1016/j.jpsychires.2007.03.005, 17512948.
27. Frey BN, Andreazza AC, Cereser KM, Martins MR, Valvassori SS, Reus GZ, Quevedo J, Kapczinski F. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci 2006, 79:281-286. 10.1016/j.lfs.2006.01.002, 16460767.
28. Angelucci F, Aloe L, Jimenez-Vasquez P, Mathe AA. Lithium treatment alters brain concentrations of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in a rat model of depression. Int J Neuropsychopharmacol 2003, 6:225-231. 10.1017/S1461145703003468, 12974988.
29. Hellweg R, Lang UE, Nagel M, Baumgartner A. Subchronic treatment with lithium increases nerve growth factor content in distinct brain regions of adult rats. Mol Psychiatry 2002, 7:604-608. 10.1038/sj.mp.4001042, 12140783.
30. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 2001, 158:100-106.
31. Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, Chuang DM. Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 2002, 43:1173-1179. 10.1016/S0028-3908(02)00217-4, 12504924.
32. Azab AN, He Q, Ju S, Li G, Greenberg ML. Glycogen synthase kinase-3 is required for optimal de novo synthesis of inositol. Mol Microbiol 2007, 63:1248-1258. 10.1111/j.1365-2958.2007.05591.x, 17257308.
33. Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A, Kaibuchi K. GSK-3β regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 2005, 120:137-149. 10.1016/j.cell.2004.11.012, 15652488.
34. Jiang H, Guo W, Liang X, Rao Y. Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3β and its upstream regulators. Cell 2005, 120:123-135.
35. Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature 2002, 417:292-295. 10.1038/417292a, 12015604.
36. Yan P, Qing G, Qu Z, Wu CC, Rabson A, Xiao G. Targeting autophagic regulation of NF-kB in HTLV-I transformed cells by geldanamycin: implications for therapeutic interventions. Autophagy 2007, 3:600-603.
37. Qu Z, Qing G, Rabson A, Xiao G. Tax deregulation of NF-kB2 p100 processing involves both b-TrCP-dependent and -independent mechanisms. J Biol Chem 2004, 279:44563-44572. 10.1074/jbc.M403689200, 15310758.
38. Qing G, Qu Z, Xiao G. Regulation of NF-κB2 p100 processing by its cis-acting domain. J Biol Chem 2005, 280:18-27.
39. Fu J, Qu Z, Yan P, Ishikawa C, Aqeilan RI, Rabson AB, Xiao G. The tumor suppressor gene WWOX links the canonical and noncanonical NF-kB pathways in HTLV-I Tax-mediated tumorigenesis. Blood 2011, 117:1652-1661. 10.1182/blood-2010-08-303073, 21115974.
40. Yan P, Fu J, Qu Z, Li S, Tanaka T, Grusby MJ, Xiao G. PDLIM2 suppresses human T-cell leukemia virus type I Tax-mediated tumorigenesis by targeting Tax into the nuclear matrix for proteasomal degradation. Blood 2009, 113:4370-4380. 10.1182/blood-2008-10-185660, 2676091, 19131544.
41. Qu Z, Fu J, Yan P, Hu J, Cheng SY, Xiao G. Epigenetic repression of PDZ-LIM domain-containing protein 2: implications for the biology and treatment of breast cancer. J Biol Chem 2010, 285:11786-11792. 10.1074/jbc.M109.086561, 2852914, 20185823.
42. Qing G, Qu Z, Xiao G. Endoproteolytic processing of C-terminally truncated NF-kB2 precursors at kappaB-containing promoters. Proc Natl Acad Sci USA 2007, 104:5324-5329. 10.1073/pnas.0609914104, 1838492, 17363471.
43. Qu Z, Yan P, Fu J, Jiang J, Grusby MJ, Smithgall TE, Xiao G. DNA methylation-dependent repression of PDZ-LIM domain-containing protein 2 in colon cancer and its role as a potential therapeutic target. Cancer Res 2010, 70:1766-1772. 10.1158/0008-5472.CAN-09-3263, 3003295, 20145149.